S59 Adherence to nebulised therapies in people with cystic fibrosis starting Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)

IntroductionCystic Fibrosis HealthHub (CFHH) is a digital platform in use by 17 adult CF centres in the UK which improves patient self-care by objectively monitoring adherence to nebulised therapies delivered via e-Track nebulisers which record device usage on a central server. This study aimed to objectively measure a perceived decrease in adherence with nebulised therapies following initiation of the Elexacaftor-Tezacaftor-Ivacaftor oral CFTR modulator therapy.MethodsWe identified all patients on Kaftrio currently enrolled in CFHH who regularly uploaded data. We compared average CFHH-measured adherence 3 months before and after starting Kaftrio. We reviewed documentation on our clinical database of any patient or healthcare professional decision to change nebuliser usage.Results154 patients were taking Kaftrio. 71 were not enrolled in CFHH, 34 did not regularly upload data, and 2 had been instructed to change therapy during the study period leaving 47 patients included in analysis. 31 patients (65%) reduced their adherence to nebulised therapies following Kaftrio use. Median nebulised therapy adherence dropped from 65% to 42% (p